By: David Ostrowsky It’s a daunting Venn diagram – the interplay of three potentially fatal diseases: Respiratory Syncytial Virus (“RSV”), COVID-19, and influenza. And with summer slipping into fall, this triple-headed monster is (once again) threatening to rear its ugly head. But, thanks to modern medicine, could this cold-weather season have a less devastating toll on humanity than what transpired a year ago? As has been well publicized this past week, there is in fact reason for optimism as updated COVID-19 vaccines from Pfizer and Moderna targeting the devilish Omicron variant XBB.1.5 will soon hit the market. It’s a promising development that, combined with the emergence of the first-ever shots to shield older adults and infants from RSV, behold potential to blunt the impact of another “tripledemic” of respiratory viruses. But naturally, the new breakthroughs have sparked a flurry of questions, some of which lack definitive answers. Is the RSV vaccine safe? Are the vaccines for RSV, COVID-19, and influenza recommended for everyone? When should one receive the vaccines? Is it effective or even safe to have multiple shots during the same visit or is separation more prudent? While federal health officials are banking on the widespread adoption of such immunizations to avoid a repeat of last winter, there is, in many cases, simply a dearth of knowledge regarding this multifaceted topic. What we do know:
Hopefully, in the coming weeks, there will be more clarity for such issues, which in turn would ease the burden on healthcare clinics, urgent care centers, and hospitals bracing for (or in some cases already dealing with) an onslaught of patients suffering from respiratory illnesses.